Panacea Acquisition Corp. (PANA.U)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Hung
Employees:
5
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO, CA 94103
(415) 754-3517

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 7.189 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.2
Price to Revenue0.0 Debt to Equity0.0 EBITDA-90.963 Million
Price to Book Value1.5858 Operating Margin0.0 Enterprise Value407.216 Million
Current Ratio34.888 EPS Growth0.067 Quick Ratio34.523
1 Yr BETA 0.1157 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-30.6984 Altman Z-Score24.7944 Free Cash Flow to Firm -73.469 Million
View SEC Filings from PANA.U instead.

View recent insider trading info

Funds Holding PANA.U (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PANA.U BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WELCH DANIEL G

  • Director
0 2021-02-10 0

FALBERG KATHRYN E

  • Director
0 2021-02-10 0

BLICKENSTAFF KIM D

  • Director
0 2021-02-10 0

HUNG DAVID PRESIDENT AND CEO

  • Officer
  • Director
  • 10% Owner
58,645,012 2021-02-10 0

OMEGA FUND V, L.P.

OMEGA FUND V GP, L.P.

OMEGA FUND V GP MANAGER, LTD.

STAMPACCHIA OTELLO

NESSI CLAUDIO

PASTER ANNE-MARI

DOIG MICHELLE

  • Director
  • 10% Owner
0 2021-02-10 0

VERNON W ANTHONY

  • Director
0 2021-02-10 0

NODELMAN OLEG

ECOR1 PANACEA HOLDINGS, LLC

ECOR1 CAPITAL FUND, L.P.

ECOR1 CAPITAL FUND QUALIFIED, L.P.

ECOR1 VENTURE OPPORTUNITY FUND, LP

ECOR1 CAPITAL, LLC

BIOTECH OPPORTUNITY GP, LLC

  • Director
  • 10% Owner
13,247,017 2021-02-10 0

HATTERSLEY GARY CHIEF SCIENTIFIC OFFICER

  • Officer
0 2021-02-10 0

BAZEMORE ROBERT B

  • Director
0 2021-02-10 0

TEMPLEMAN THOMAS SVP, PHARMACEUTICAL OPS

  • Officer
0 2021-02-10 0

YURASOV SERGEY CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-10 0

MARKEL STACY SVP, HUMAN RESOURCES

  • Officer
0 2021-02-10 0

FOX JENNIFER A. CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-10 0

BRADBURY DANIEL

  • Director
0 2020-06-30 0

PA CO-INVESTMENT LLC

COWEN INVESTMENTS II LLC

RCG LV PEARL LLC

COWEN INC.

SOLOMON JEFFREY M

  • 10% Owner
0 2020-06-30 0

HASNAIN FAHEEM

  • Director
0 2020-06-30 0

SHARP SHALINI

  • Director
0 2020-06-30 0

COOPER GRAHAM K

  • Director
0 2020-06-30 0

MARRIOTT SARAH SECRETARY

  • Officer
  • Director
0 2020-06-30 0

PERLEN SCOTT CHIEF FINANCIAL OFFICER

  • Officer
0 2020-06-30 0

STOUT CAROLINE CHIEF INVESTMENT OFFICER

  • Officer
0 2020-06-30 0

PLATSHON SCOTT CHIEF OPERATING OFFICER

  • Officer
0 2020-06-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments